Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629437 | 0.88 | AR (0.37) | ARPGRHDAC1PPARGPPARD | |
| SCHEMBL14735643 | 0.82 | AR (0.40) | ARPGR | |
| SCHEMBL14735727 | 0.81 | AR (0.39) | ARPGRHDAC1IGF1RPPARG | |
| SCHEMBL629441 | 0.81 | AR (0.39) | ARPGRIGF1R | |
| SCHEMBL630661 | 0.80 | AR (0.44) | ARPGRIGF1R | |
| SCHEMBL629373 | 0.79 | AR (0.49) | ARPGRHDAC1IGF1R | |
| SCHEMBL631033 | 0.79 | AR (0.37) | ARPGRHDAC1IGF1RPPARG | |
| SCHEMBL629598 | 0.76 | AR (0.41) | ARPGR | |
| SCHEMBL891215 | 0.76 | AR (0.46) | ARPGRHDAC1 | |
| SCHEMBL628964 | 0.76 | AR (0.37) | ARPGRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710091-B2 | Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug | IPSEN PHARMA S.A.S. (FR) | 2014-04-29 | — | — | US | disclosed |
| EP-2419410-B1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA SAS (FR) | 2013-03-06 | — | — | EP | disclosed |
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-04-05 | — | — | US | disclosed |
| EP-2419410-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010119193-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | MKI67, CCND2, CCND1 | AR 1752/4885PGR 765/4885HDAC1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.